A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease

ACS Nano

Volumn 8, Issue 3, 2014, Pages 2148-2160

  Hunter, Zoe ^a   McCarthy, Derrick P ^a   Yap, Woon Teck ^b   Harp, Christopher T ^a   Getts, Daniel R ^a   Shea, Lonnie D ^b   Miller, Stephen D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Northwestern University   (United States)

Author keywords

anergy; autoimmune disease; experimental autoimmune encephalomyelitis; multiple sclerosis; PLG nanoparticles; regulatory T cells; tolerance

Indexed keywords

CELLS; CYTOLOGY; DISEASE CONTROL; EPITOPES; ETHYLENE; FITS AND TOLERANCES; NANOPARTICLES; PEPTIDES; T-CELLS;

ANERGY; AUTOIMMUNE DISEASE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MULTIPLE SCLEROSIS; REGULATORY T CELLS;

DISEASES;

ANTIGEN; CYTOKINE; DRUG CARRIER; LACTIC ACID; MALEIC ACID DERIVATIVE; METHOXYETHYLENE-MALEIC ANHYDRIDE COPOLYMER; NANOPARTICLE; PEPTIDE FRAGMENT; POLY(MALEIC ANHYDRIDE METHYL VINYL ETHER); POLYETHYLENE DERIVATIVE; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL; ARTICLE; BIOSYNTHESIS; BRAIN; CHEMISTRY; DRUG EFFECT; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; METHODOLOGY; MOUSE; RECURRENT DISEASE; SAFETY; SPINAL CORD; T LYMPHOCYTE;

ANIMALS; ANTIGENS; BRAIN; CYTOKINES; DRUG CARRIERS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNOSUPPRESSION; LACTIC ACID; MALEATES; MICE; NANOPARTICLES; PEPTIDE FRAGMENTS; POLYETHYLENES; POLYGLYCOLIC ACID; RECURRENCE; SAFETY; SPINAL CORD; T-LYMPHOCYTES;

EID: 84896960190     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn405033r     Document Type: Article

References (53)

1. American Autoimmune Related Diseases Association The Cost Burden of Autoimmune Disease: The Latest Front in the War on Healthcare Spending; AARDA: Eastpointe, MI, 2011. http://www.aarda.org/pdf/cbad.pdf.
2. Chatenoud, L.; Thervet, E.; Primo, J.; Bach, J. F. Anti-CD3 Antibody Induces Long-Term Remission of Overt Autoimmunity in Nonobese Diabetic Mice Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 123-127
3. Chatenoud, L.; Primo, J.; Bach, J. F. CD3 Antibody-Induced Dominant Self Tolerance in Overtly Diabetic Nod Mice J. Immunol. 1997, 158, 2947-2954
4. Belghith, M.; Bluestone, J. A.; Barriot, S.; Megret, J.; Bach, J. F.; Chatenoud, L. Tgf-Beta-Dependent Mechanisms Mediate Restoration of Self-Tolerance Induced by Antibodies to CD3 in Overt Autoimmune Diabetes Nat. Med. 2003, 9, 1202-1208
5. + T Cell Unresponsiveness and Functional Reversal of Established Experimental Autoimmune Encephalomyelitis J. Immunol. 2005, 174, 4525-4534
6. Herold, K. C.; Hagopian, W.; Auger, J. A.; Poumian-Ruiz, E.; Taylor, L.; Donaldson, D.; Gitelman, S. E.; Harlan, D. M.; Xu, D.; Zivin, R. A. et al. Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus N. Eng. J. Med. 2002, 346, 1692-1698
7. Miller, S. D.; Vanderlugt, C. L.; Lenschow, D. J.; Pope, J. G.; Karandikar, N. J.; Dal Canto, M. C.; Bluestone, J. A. Blockade of Cd28/B7-1 Interaction Prevents Epitope Spreading and Clinical Relapses of Murine EAE Immunity 1995, 3, 739-745
8. Kuchroo, V. K.; Das, M. P.; Brown, J. A.; Ranger, A. M.; Zamvil, S. S.; Sobel, R. A.; Weiner, H. L.; Nabavi, N.; Glimcher, L. H. B7-1 and B7-2 Costimulatory Molecules Differentially Activate the Th1/Th2 Developmental Pathways: Application to Autoimmune Disease Therapy Cell 1995, 80, 707-718
9. Karpus, W. J.; Lukacs, N. W.; McRae, B. L.; Streiter, R. M.; Kunkel, S. L.; Miller, S. D. An Important Role for the Chemokine Macrophage Inflammatory Protein-1 Alpha in the Pathogenesis of the T Cell-Mediated Autoimmune Disease, Experimental Autoimmune Encephalomyelitis J. Immunol. 1995, 155, 5003-5010
10. Ruddle, N. H.; Bergman, C. M.; McGrath, K. M.; Lingenheld, E. G.; Grunnet, M. L.; Padula, S. J.; Clark, R. B. An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis J. Exp. Med. 1990, 172, 1193-1200
11. Yednock, T. A.; Cannon, C.; Fritz, L. C.; Sanchez-Madrid, F.; Steinman, L.; Karin, N. Prevention of Experimental Autoimmune Encephalomyelitis by Antibodies against ?4β1 Integrin Nature 1992, 356, 63-66
12. Miller, D. H.; Khan, O. A.; Sheremata, W. A.; Blumhardt, L. D.; Rice, G. P.; Libonati, M. A.; Willmer-Hulme, A. J.; Dalton, C. M.; Miszkiel, K. A.; O'Connor, P. W. A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis N. Eng. J. Med. 2003, 348, 15-23
13. Langer-Gould, A.; Atlas, S. W.; Green, A. J.; Bollen, A. W.; Pelletier, D. Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab N. Eng. J. Med. 2005, 353, 375-381
14. Klotz, L.; Wiendl, H. Monoclonal Antibodies in Neuroinflammatory Diseases Expert Opin. Biol. Ther. 2013, 13, 831-846
15. Kleinschmidt-DeMasters, B. K.; Tyler, K. L. Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis N. Eng. J. Med. 2005, 353, 369-374
16. Kitsos, D. K.; Tsiodras, S.; Stamboulis, E.; Voumvourakis, K. I. Rituximab and Multiple Sclerosis Clin. Neuropharmacol. 2012, 35, 90-96
17. Miller, S. D.; Turley, D. M.; Podojil, J. R. Antigen-Specific Tolerance Strategies for the Prevention and Treatment of Autoimmune Disease Nat. Rev. Immunol. 2007, 7, 665-677
18. Luo, X.; Herold, K. C.; Miller, S. D. Immunotherapy of Type 1 Diabetes: Where Are We and Where Should We Be Going? Immunity 2010, 32, 488-499
19. Bielekova, B.; Goodwin, B.; Richert, N.; Cortese, I.; Kondo, T.; Afshar, G.; Gran, B.; Eaton, J.; Antel, J.; Frank, J. A. et al. Encephalitogenic Potential of the Myelin Basic Protein Peptide (Amino Acids 83-99) in Multiple Sclerosis: Results of a Phase II Clinical Trial with an Altered Peptide Ligand Nat. Med. 2000, 6, 1167-1175
20. Wraith, D. C.; Smilek, D. E.; Mitchell, D. J.; Steinman, L.; McDevitt, H. O. Antigen Recognition in Autoimmune Encephalomyelitis and the Potential for Peptide-Mediated Immunotherapy Cell 1989, 59, 247-255
21. Nicholson, L. B.; Greer, J. M.; Sobel, R. A.; Lees, M. B.; Kuchroo, V. K. An Altered Peptide Ligand Mediates Immune Deviation and Prevents Autoimmune Encephalomyelitis Immunity 1995, 3, 397-405
22. Kennedy, M. K.; Tan, L. J.; Dal Canto, M. C.; Tuohy, V. K.; Lu, Z. J.; Trotter, J. L.; Miller, S. D. Inhibition of Murine Relapsing Experimental Autoimmune Encephalomyelitis by Immune Tolerance to Proteolipid Protein and Its Encephalitogenic Peptides J. Immunol. 1990, 144, 909-915
23. Tan, L. J.; Kennedy, M. K.; Miller, S. D. Regulation of the Effector Stages of Experimental Autoimmune Encephalomyelitis Via Neuroantigen-Specific Tolerance Induction. II. Fine Specificity of Effector T Cell Inhibition J. Immunol. 1992, 148, 2748-2755
24. Getts, D. R.; Turley, D. M.; Smith, C. E.; Harp, C. T.; McCarthy, D.; Feeney, E. M.; Getts, M. T.; Martin, A. J.; Luo, X.; Terry, R. L. et al. Tolerance Induced by Apoptotic Antigen-Coupled Leukocytes Is Induced by Pd-L1+ and Il-10-Producing Splenic Macrophages and Maintained by T Regulatory Cells J. Immunol. 2011, 187, 2405-2417
25. Vanderlugt, C. L.; Eagar, T. N.; Neville, K. L.; Nikcevich, K. M.; Bluestone, J. A.; Miller, S. D. Pathologic Role and Temporal Appearance of Newly Emerging Autoepitopes in Relapsing Experimental Autoimmune Encephalomyelitis J. Immunol. 2000, 164, 670-678
26. Lutterotti, A.; Yusef, S.; Sputtek, A.; Sturner, K.; Stellmann, J.-P.; Breiden, P.; Reinhardt, S.; Schulze, C.; Bester, M.; Heesen, C. et al. Antigen-Specific Tolerance by Autologous Myelin Peptide-Coupled Cells: A Phase 1 Trial in Multiple Sclerosis Sci. Transl. Med. 2013, 5, 188ra75
27. Getts, D. R.; Martin, A. J.; McCarthy, D. P.; Terry, R. L.; Hunter, Z. H.; Yap, W. T.; Getts, M. T.; Pleiss, M.; Luo, X.; King, N. J. C. et al. Microparticles Bearing Encephalitogenic Peptides Induce T-Cell Tolerance and Ameliorate Experimental Autoimmune Encephalomyelitis Nat. Biotechnol. 2012, 30, 1217-1224
28. Turley, D. M.; Miller, S. D. Peripheral Tolerance Induction Using Ethylenecarbodiimide-Fixed Apcs Uses Both Direct and Indirect Mechanisms of Antigen Presentation for Prevention of Experimental Autoimmune Encephalomyelitis J. Immunol. 2007, 178, 2212-2220
29. Viorritto, I. C.; Nikolov, N. P.; Siegel, R. M. Autoimmunity versus Tolerance: Can Dying Cells Tip the Balance? Clin. Immunol. 2007, 122, 125-134
30. Lutsiak, M. E.; Kwon, G. S.; Samuel, J. Biodegradable Nanoparticle Delivery of a Th2-Biased Peptide for Induction of Th1 Immune Responses J. Pharm. Pharmacol. 2006, 58, 739-747
31. Batanero, E.; Barral, P.; Villalba, M.; Rodriguez, R. Biodegradable Poly (DL-Lactide Glycolide) Microparticles as a Vehicle for Allergen-Specific Vaccines: A Study Performed with Ole E 1, the Main Allergen of Olive Pollen J. Immunol. Methods 2002, 259, 87-94
32. McCarthy, D. P.; Richards, M. H.; Miller, S. D. Mouse Models of Multiple Sclerosis: Experimental Autoimmune Encephalomyelitis and Theiler's Virus-Induced Demyelinating Disease Methods Mol. Biol. 2012, 900, 381-401
33. McMahon, E. J.; Bailey, S. L.; Castenada, C. V.; Waldner, H.; Miller, S. D. Epitope Spreading Initiates in the CNS in Two Mouse Models of Multiple Sclerosis Nat. Med. 2005, 11, 335-339
34. Smith, C. E.; Eagar, T. N.; Strominger, J. L.; Miller, S. D. Differential Induction of Ige-Mediated Anaphylaxis after Soluble vs Cell-Bound Tolerogenic Peptide Therapy of Autoimmune Encephalomyelitis Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 9595-9600
35. Kutscher, H. L.; Gao, D.; Li, S.; Massa, C. B.; Cervelli, J.; Deshmukh, M.; Joseph, L. B.; Laskin, D. L.; Sinko, P. J. Toxicodynamics of Rigid Polystyrene Microparticles on Pulmonary Gas Exchange in Mice: Implications for Microemboli-Based Drug Delivery Systems Toxicol. Appl. Pharmacol. 2013, 266, 214-223
36. Getts, D. R.; Terry, R. L.; Getts, M. T.; Deffrasnes, C.; Muller, M.; van Vredent, C.; Ashhurst, T. M.; Chami, B.; McCarthy, D. P.; Wu, H. et al. Therapeutic Inflammatory Monocyte Modulation Using Immune-Modifying Microparticles Sci. Transl. Med. 2014, 6 219ra7
37. Chong, C. S.; Cao, M.; Wong, W. W.; Fischer, K. P.; Addison, W. R.; Kwon, G. S.; Tyrrell, D. L.; Samuel, J. Enhancement of T Helper Type 1 Immune Responses against Hepatitis B Virus Core Antigen by Plga Nanoparticle Vaccine Delivery J. Controlled Release 2005, 102, 85-99
38. Nixon, D. F.; Hioe, C.; Chen, P. D.; Bian, Z.; Kuebler, P.; Li, M. L.; Qiu, H.; Li, X. M.; Singh, M.; Richardson, J. et al. Synthetic Peptides Entrapped in Microparticles Can Elicit Cytotoxic T Cell Activity Vaccine 1996, 14, 1523-1530
39. Jenkins, M. K.; Schwartz, R. H. Antigen Presentation by Chemically Modified Splenocytes Induces Antigen-Specific T Cell Unresponsiveness in Vitro and in Vivo J. Exp. Med. 1987, 165, 302-319
40. Keegan, M. E.; Falcone, J. L.; Leung, T. C.; Saltzman, M. Biodegradable Microspheres with Enhanced Capacity for Covalently Bound Surface Ligands Macromolecules 2004, 37, 9979-9784
41. Champion, J. A.; Mitragotri, S. Role of Target Geometry in Phagocytosis Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 4930-4934
42. Areschoug, T.; Gordon, S. Scavenger Receptors: Role in Innate Immunity and Microbial Pathogenesis Cell. Microbiol. 2009, 11, 1160-1169
43. Dobrovolskaia, M. A.; McNeil, S. E. Immunological Properties of Engineered Nanomaterials Nat. Nanotechnol. 2007, 2, 469-478
44. Sahoo, S. K.; Panyam, J.; Prabha, S.; Labhasetwar, V. Residual Polyvinyl Alcohol Associated with Poly(D,L-lactide-co-glycolide) Nanoparticles Affects Their Physical Properties and Cellular Uptake J. Controlled Release 2002, 82, 105-114
45. Rodriguez, P. L.; Harada, T.; Christian, D. A.; Pantano, D. A.; Tsai, R. K.; Discher, D. E. Minimal "Self" Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles Science 2013, 339, 971-975
46. Lundqvist, M.; Stigler, J.; Elia, G.; Lynch, I.; Cedervall, T.; Dawson, K. A. Nanoparticle Size and Surface Properties Determine the Protein Corona with Possible Implications for Biological Impacts Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 14265-14270
47. Kobayashi, N.; Kobayashi, H.; Gu, L.; Malefyt, T.; Siahaan, T. J. Antigen-Specific Suppression of Experimental Autoimmune Encephalomyelitis by a Novel Bifunctional Peptide Inhibitor J. Pharmacol. Exp. Ther. 2007, 322, 879-886
48. Zhao, H.; Kiptoo, P.; Williams, T. D.; Siahaan, T. J.; Topp, E. M. Immune Response to Controlled Release of Immunomodulating Peptides in a Murine Experimental Autoimmune Encephalomyelitis (EAE) Model J. Controlled Release 2010, 141, 145-152
49. Huang, L.; Lemos, H. P.; Li, L.; Li, M.; Chandler, P. R.; Baban, B.; McGaha, T. L.; Ravishankar, B.; Lee, J. R.; Munn, D. H. et al. Engineering DNA Nanoparticles as Immunomodulatory Reagents That Activate Regulatory T Cells J. Immunol. 2012, 188, 4913-4920
50. Yeste, A.; Nadeau, M.; Burns, E. J.; Weiner, H. L.; Quintana, F. J. Nanoparticle-Mediated Codelivery of Myelin Antigen and a Tolerogenic Small Molecule Suppresses Experimental Autoimmune Encephalomyelitis Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 11270-11275
51. Jager, A.; Dardalhon, V.; Sobel, R. A.; Bettelli, E.; Kuchroo, V. K. Th1, Th17, and Th9 Effector Cells Induce Experimental Autoimmune Encephalomyelitis with Different Pathological Phenotypes J. Immunol. 2009, 183, 7169-7177
52. Tompkins, S. M.; Padilla, J.; Dal Canto, M. C.; Ting, J. P.; Van Kaer, L.; Miller, S. D. De Novo Central Nervous System Processing of Myelin Antigen Is Required for the Initiation of Experimental Autoimmune Encephalomyelitis J. Immunol. 2002, 168, 4173-4183
53. Bailey, S. L.; Schreiner, B.; McMahon, E. J.; Miller, S. D. CNS Myeloid DCs Presenting Endogenous Myelin Peptides 'Preferentially' Polarize CD4(+) T(H)-17 Cells in Relapsing EAE Nat. Immunol. 2007, 8, 172-180